AllianceBernstein’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

AllianceBernstein’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-41,100	Closed	-$4.41M	–	3312
2023 Q1	$4.41M	Buy	41,100 +10,600	+35%	+$1.22M	﹤0.01%	1449
2022 Q4	$3.35M	Sell	30,500 -600	-2%	-$38.9K	﹤0.01%	1617
2022 Q3	$1.83M	Hold	31,100	–	–	﹤0.01%	1943
2022 Q2	$878K	Buy	31,100 +900	+3%	+$26.1K	﹤0.01%	2417
2022 Q1	$1.14M	Buy	+30,200	New	+$1.19M	﹤0.01%	2377

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

AllianceBernstein's RXDX Position: Q2 2023 in Review

AllianceBernstein sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 41,100 shares — an estimated $4.41M sold.

AllianceBernstein first reported a position in RXDX in Q1 2022 and held it in 5 quarters. The position peaked at $4.41M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

AllianceBernstein reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
AllianceBernstein sold 41,100 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $4.41M.
AllianceBernstein first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
AllianceBernstein's Prometheus Biosciences, Inc. Common Stock position peaked at $4.41M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on AllianceBernstein's 13F filing for Q2 2023, filed 15 Aug 2023.